公开(公告)号：WO2022053685A2

公开(公告)日：2022-03-17

申请号：PCT/EP2021/075116

申请日：2021-09-13

Applicant: MEDIMMUNE LIMITED

Inventor： SCHMIDT, Guenter ,  BRIEU, Nicolas ,  SPITZMUELLER, Andreas ,  KAPIL, Ansh ,  TAN, Tze, Heng ,  WORTMANN, Philipp

IPC: G06K9/00 ,  C07K16/28 ,  C07K16/30 ,  G06K9/62 ,  C07K16/2827 ,  G06K9/6215 ,  G06K9/6271 ,  G06K9/6292 ,  G06V10/454 ,  G06V20/695 ,  G06V20/698

Abstract: The present invention relates to a method for predicting how a cancer patient will respond to an antibody drug conjugate (ADC) therapy involving computing a predictive response score based on single-cell ADC scores for each cancer cell. For each cancer cell, a single-cell ADC score is computed based on the staining intensities of the dye in the membrane and cytoplasm of the cancer cell and in the membranes and cytoplasms of neighboring cancer cells. The present invention also relates to predicting a response of a cancer patient to ADC therapy by aggregating all single-cell ADC scores of the tissue sample using a statistical operation, and the subsequent treatment of cancer with related antibody-drug conjugates.